-
Company Insights
New![]()
Innovation and Patenting activity of Telefonaktiebolaget LM Ericsson Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Telefonaktiebolaget LM Ericsson Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-108 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-108 in Solid Tumor Drug Details: LM-108 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Ovarian Cancer Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Colorectal Cancer Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Pancreatic Cancer Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Gastric Cancer Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Solid Tumor Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Esophageal Cancer Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-108 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-108 in Solid Tumor Drug Details: LM-108 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: LM-302 is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.